Canadian Recommendations for Glioblastoma Treatment
Author Information
Author(s): Warren P. Mason, Rolando Del Maestro, David Eisenstat, Peter Forsyth, Dorcas Fulton, Normand Laperriere, David Macdonald, James Perry, Brian Thiessen
Primary Institution: Princess Margaret Hospital, University of Toronto
Conclusion
The addition of temozolomide chemotherapy to the standard treatment has significantly increased the survival rate of glioblastoma patients.
Supporting Evidence
- Patients receiving radiotherapy and surgery had a median survival of 11 months.
- 2-year survival was 26.5% with the combination of radiotherapy and temozolomide compared to 10.4% with radiotherapy alone.
- Temozolomide is recommended for newly diagnosed glioblastoma and recurrent high-grade gliomas.
Takeaway
Doctors have new guidelines to help treat brain cancer better, which can help patients live longer.
Methodology
The recommendations were developed by a multidisciplinary panel based on level 1 evidence.
Limitations
The study highlights the need for further research to improve treatment outcomes.
Participant Demographics
Glioblastoma is more common in males and typically diagnosed in patients in their sixth or seventh decade.
Want to read the original?
Access the complete publication on the publisher's website